yttrium radioisotopes has been researched along with Local Neoplasm Recurrence in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.59) | 18.7374 |
| 1990's | 5 (7.94) | 18.2507 |
| 2000's | 22 (34.92) | 29.6817 |
| 2010's | 29 (46.03) | 24.3611 |
| 2020's | 6 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Adhikarla, V; Bading, J; Cao, T; Chen, R; Colcher, D; Dandapani, S; Forman, SJ; Herrera, AF; Karras, N; McTague, P; Mei, M; Nademanee, A; Palmer, J; Poku, EK; Popplewell, L; Sahebi, F; Shively, JE; Simpson, J; Smith, DL; Smith, E; Song, J; Spielberger, R; Thomas, SH; Tsai, NC; Wong, J; Wu, AM; Yamauchi, D; Yazaki, P | 1 |
| Akarca, US; Akhan, O; Bilgiç, S; Bozkurt, MF; Çakaloğlu, Y; Cantaşdemir, M; Çapa Kaya, G; Çermik, TF; Er, Ö; Ilgıt, E; Küçük, NÖ; Numan, F; Parıldar, M; Türkmen, C | 1 |
| Akateh, C; Black, SM; Cloyd, JM; Conteh, L; Elliott, E; Miller, ED; Noonan, A; Pawlik, TM; Tsung, A | 1 |
| Baltacioglu, F; Calik, A; Cobanoglu, U; Kucukaslan, H; Oguz, S; Ones, T; Topaloglu, S | 1 |
| Karatoprak, S; Kutlu, R | 1 |
| Argiriadi, P; Bekki, Y; Facciuto, L; Facciuto, ME; Gunasekaran, G; Kamath, A; Kim, E; Lewis, S; Marti, J; Patel, RS; Schiano, TD; Simpson, W; Toshima, T | 1 |
| Clerc, D; Demartines, N; Halkic, N; Melloul, E | 1 |
| Abeccassis, M; Abouchaleh, N; Ali, R; Asadi, AA; Atassi, R; Baker, T; Caicedo, JC; Desai, K; Fryer, J; Gabr, A; Ganger, D; Habib, A; Hickey, R; Hohlastos, E; Kulik, L; Lewandowski, RJ; Memon, K; Riaz, A; Salem, R; Vouche, M | 1 |
| Bahary, N; Bartlett, DL; Choudry, MHA; Dhir, M; Geller, DA; Hogg, ME; Holtzman, MP; Jones, HL; Pingpank, JF; Tsung, A; Wallis Marsh, J; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Dadia, S; Drexler, M; Farkash, U; Frenkel Rutenberg, T; Gortzak, Y; Kollender, Y; Kramer, M; Morag, G; Rath, E; Sternheim, A; Vitenberg, M | 1 |
| Abecassis, M; Abouchaleh, N; Ali, R; Baker, T; Caicedo, J; Gabr, A; Katariya, N; Lewandowski, RJ; Riaz, A; Salem, R | 1 |
| Arreaza, JA; Stauffer, JA; Tsamalaidze, L | 1 |
| Bagni, O; Cianni, R; Di Costanzo, GG; Filippi, L; Pelle, G; Schillaci, O; Tortora, R | 1 |
| Belli, ML; Cicone, F; Cremonesi, M; Ferrari, ME; Guidi, C; Paganelli, G; Sarnelli, A; Wahl, R | 1 |
| Kim, HC | 1 |
| Abayaweera, G; Abou-Taleb, HA; AbouElhassan, KM; AbouTaleb, HA; Adair, LS; Adams, E; Addison, O; Addy, I; Akhtar, N; Alten, B; Anesini, J; Añez, R; Angaridis, PA; Aouba, A; Arakawa, K; Aumeeruddy-Elalfi, Z; Bao, LP; Basu, E; Bayraktar, E; Bekkelund, CS; Bell, J; Beraldo, H; Bermúdez, V; Betenbaugh, MJ; Bhattacharya, R; Bienvenu, B; Bolzoni, M; Bootz, F; Borja, JB; Bove, DG; Bowden, ME; Bradsher, C; Brockstedt, D; Brothers, RM; Buschauer, A; Calandriello, L; Caporossi, A; Carba, DB; Carratalà, J; Castella, B; Caviezel, D; Ceccato, R; Charalambidis, G; Charisiadis, A; Chattopadhyay, P; Chen, Q; Chen, W; Chen, Y; Chen, YT; Chen, ZJ; Chen, ZY; Cheng, MA; Cheng, ZB; Cherevko, S; Cheung, IY; Cheung, NV; Chiappini, A; Chiu, YL; Choi, IG; Chough, S; Chung, CY; Cobb, A; Colotto, A; Continentino, MA; Cook, AJMC; Costa, F; Coutsolelos, AG; Cuperus, N; Curtis, BM; Davenport, AJ; de Boysson, H; Dela, F; Deng, XP; Deshayes, S; Dhara, K; Dietrich, D; Dietrich, J; Dilhari, A; Ding, R; Ding, Y; Dirè, S; Dohlmann, TL; Dotsenko, A; Doubrovina, E; Du, K; Du, ZJ; Duvic, M; Eastman, A; Eliakim-Raz, N; Elz, S; Emile, JF; Emmerling, C; Engelhard, MH; Eriksson, JG; Etzold, BJM; Faini, AC; Falsini, B; Farmer, E; Fei, JJ; Ferreira, IP; Föttinger, K; Franconieri, F; Fryda, NJ; Fuentes, I; Galateau-Sallé, F; Ganguly, M; Gani, BA; Gao, X; Gao, XF; Gao, XJ; García-Mendiola, T; Garg, A; Gascon, J; Gayani, B; Gevensleben, H; Gilbert, M; Giudiceandrea, A; Giuliani, N; Gocmen, AY; Goldman, DA; Goltz, D; Gombert, AK; Gomila, A; Goodwin, P; Górnicki, K; Gostin, PF; Graterol, M; Gremillet, C; Grier, S; Grün, AL; Gusakov, A; Halldórsdóttir, HR; Han, L; Han, Z; Hävecker, M; Helge, JW; Heo, K; Hernández, JD; Hindsø, M; Holmen Olofsson, G; Hong, CE; Hong, J; Horenstein, AL; Hosenally, M; Hruz, P; Hsu, HL; Hsu, KC; Hu, SF; Hu, Y; Huang, K; Huang, S; Huang, WH; Humaira, A; Hung, CF; Hung, WS; Huo, XK; Huvinen, E; Idorn, M; Ignatyev, K; Im, WT; Ismaël, IS; Jakobsson, JG; Janaszek-Mańkowska, M; Jeong, GT; Ji, L; Ji, X; Jiang, Y; Jo, IH; Jo, SH; Johnson, AC; Johnson, LE; Kadirvelu, K; Kahnt, A; Kaleta, A; Kamiya, T; Kang, DH; Kang, XH; Kashiwagi, T; Katayama, E; Kawachi, N; Keller, M; Kellermann, L; Khan, T; Khan, ZA; Kharshoum, RM; Khim, JS; Kikuchi, M; Kim, BS; Kim, DS; Kim, DW; Kim, JH; Kim, JJ; Kim, JU; Kim, SK; Kim, WS; Kimura, J; Kiss, C; Knop-Gericke, A; Kobayashi, S; Koivusalo, SB; Kolar, E; Kottegoda, N; Kramer, K; Kristiansen, G; Kruger, AA; Kumar, S; Kumar, V; Kumarage, S; Kursungoz, C; Kushner, BH; Kuwahara, F; Kuzawa, C; Kwon, BO; Landsberg, J; Larsen, S; Lauer, P; Le Luduec, JB; Lee, DW; Lee, H; Lee, HY; Lee, JW; Lee, MJ; Lee, SW; Lefrançois, P; Leibovici, L; Leong, KK; Leong, M; Li, B; Li, D; Li, G; Li, J; Li, YZ; Liang, JH; Liang, X; Liens, A; Ligorio, G; Lin, JD; Lindholm, MG; Liou, MJ; List-Kratochvil, EJW; Litvinov, IV; Liu, F; Liu, S; Liu, Y; Liu, Z; Lohar, S; Lopes, MTP; Lorenzo, E; Lu, X; Lukashuk, L; Lukens, WL; Luo, HR; Luo, L; Luttik, MAH; Ma, Y; MacGowan, A; Mahomoodally, MF; Maissen, S; Malavasi, F; Malhotra, M; Mallik, S; Manna, D; Mans, R; Marangoni, D; Marimpietri, D; Marques, F; Marques, WL; Marsaa, K; Martin Silva, N; Martinez, A; Martínez, MS; Massaia, M; Mayrhofer, KJJ; McDade, T; McNeel, DG; Met, Ö; Micalizio, GC; Modak, S; Morandi, F; Moreau, L; Morla, S; Morrell, AP; Morris, S; Mubarak, Z; Muchlisin, ZA; Munoz, M; Nagao, Y; Nakama, T; Nakamura, H; Nakano, T; Nardi, MV; Nasirian, A; Nelson, MD; Netchiporouk, E; Ni, X; Niess, JH; Nijenhuis, JM; Nikolaou, V; O'Connor, BJ; O'Reilly, RJ; Odobel, F; Ohata, C; Ohyama, B; Olivar, LC; Ordoñez, MG; Ostrovnaya, I; Palmar, J; Panda, S; Pandiyarajan, S; Park, B; Park, H; Park, JH; Park, S; Pasquali, L; Patik, JC; Pearce, CI; Peele, ME; Peng, S; Perera, IC; Petty, JT; Pidko, EA; Pinheiro, CB; Pistoia, V; Pita, M; Planchat, A; Plass, F; Pockes, S; Pradhan, N; Premasudha, P; Pronk, JT; Provost, N; Pujol, M; Qi, P; Qiu, J; Qiu, Z; Quan, J; Quaranta, A; Ra, CH; Rameshan, R; Ranglack, DH; Rausch-Fan, X; Rieger, E; Rivas, JR; Roberts, SS; Rocha, WR; Rodrigues, GLS; Rojas, J; Roy, P; Rozhkova, A; Rufo, S; Rupprechter, G; Saeui, CT; Saha, A; Sakai, M; Salazar, J; Salem, HF; Salgarello, T; Samarakoon, SR; Sandau, C; Sandbeck, DJS; Santos, AF; Santos, VG; Sara, Y; Saslow, SA; Sasseville, D; Sato, S; Sauer, JD; Schlögl, R; Schweiger, MJ; Shashkov, I; Shaw, E; Shen, WQ; Shim, J; Shu, J; Singh, C; Sinha Babu, SP; Sinitsyn, A; Sinitsyna, O; Skadborg, SK; Song, Q; Song, W; Stach-Lempinen, B; Stoddart, M; Stoica, M; Street, SR; Sukwong, P; Sun, CP; Sun, J; Sunwoo, IY; Suresh, S; Szécsényi, Á; Takahashi, T; Takeda, S; Tang, D; Tas, ST; Tebé, C; Teixeira, LR; Teixidor, F; Terrier, B; Teschner, D; Tetzlaff, MT; Theisen, E; Thor Straten, P; Tiitinen, A; Timpel, M; Toccoli, T; Torikai, K; Torres, W; Toscani, D; Trad, S; Tsai, HJ; Tseng, CP; Tucker, WJ; Um, W; Vallejo-Torres, L; van den Broek, M; Van den Heuvel, L; van der Woude, LN; van Maris, AJA; Van Schepdael, A; Vank, C; Verucchi, R; Vigo, JM; Viñas, C; Vogt, TJ; Vuong, C; Wai, H; Wang, B; Wang, D; Wang, H; Wang, JJ; Wang, K; Wang, L; Wang, Q; Wang, YR; Watanabe, S; Watters, AK; Weerasekera, MM; Wei, L; Wheeler, DA; Wiegand, I; Wifling, D; Wijesinghe, GK; Winiczenko, R; Wolker, T; Wu, J; Wu, TC; Wu, YY; Xie, P; Xie, YP; Xu, A; Xu, E; Xu, L; Xu, Z; Yamaguchi, M; Yang, A; Yang, G; Yang, J; Yang, TM; Yang, W; Yang, Y; Yarema, KJ; Yesiltepe, M; Yi, KJ; Yigit, N; Yim, UH; Yin, B; Yu, S; Zengin, G; Zhang, B; Zhang, C; Zhang, GR; Zhang, H; Zhang, J; Zhang, L; Zhang, TY; Zhang, X; Zhang, Y; Zhang, YX; Zhao, H; Zhao, JC; Zhao, Z; Zheng, R; Zhou, W; Zorn Morales, N | 1 |
| Baur-Melnyk, A; Birkenmaier, C; Capellen, CF; Dürr, HR; Jansson, V; Klein, A; Tiling, R | 1 |
| Dlugosz-Danecka, M; Giza, A; Gruszka, AM; Hubalewska-Dydejczyk, A; Jakobczyk, M; Jurczak, W; Kisiel, E; Knopińska-Posłuszny, W; Krawczyk, K; Skotnicki, A; Sowa Staszczak, A; Szostek, M; Szymczyk, M; Wróbel, T; Zimowska-Curylo, D; Zinzani, PL | 1 |
| Forero-Torres, A; Knox, SJ; LoBuglio, AF; Meredith, RF; Micallef, IN; Shah, JJ; Shen, S; Vaklavas, C | 1 |
| Brody, LA; Capanu, M; Carrasquillo, JA; Chou, JF; Do, KG; Garcia, AR; Kemeny, NE; Longing, AP; Pandit-Taskar, N; Petre, EN; Sofocleous, CT | 1 |
| Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M | 1 |
| Coveler, A; Harris, WP; Kwan, SW; Monsky, WL; Padia, SA; Roudsari, B | 1 |
| Goldenberg, DM; Kio, EA; Misleh, JG; Sharkey, RM; Tomblyn, MB; Wegener, WA; Witzig, TE | 1 |
| Abad, J; Bowser, I; Gulec, S; Henry, LR; Hostetter, RB; Ressler, B; Schwarz, RE; Vaghefi, H; Yan, M | 1 |
| Banz, Y; Klaeser, B; Koechli, V; Mueller, BU; Pabst, T | 1 |
| Boucher, E; Boudjema, K; Edeline, J; Garin, E; Levi Sandri, GB; Meunier, B; Rayar, M; Sulpice, L | 1 |
| Bergmann, L; Dreyling, M; Ferrero, S; Finke, J; Forstpointner, R; Ghione, P; Hiddemann, W; Keller, U; Passera, R; Pastore, A; Pezzutto, A; Scholz, CW; Trümper, L; Unterhalt, M; Weigert, O | 1 |
| Ascanio, S; Brandi, G; Cappelli, A; Cucchetti, A; Golfieri, R; Gramenzi, A; Monari, F; Mosconi, C; Pettinato, C; Renzulli, M; Trevisani, F | 1 |
| Bal, CS; Gupta, SK; Malhotra, A; Sharma, A; Singla, S; Snehlata, EY; Thakral, P; Tyagi, JS; Vashist, A; Yadav, MP | 1 |
| Abuodeh, Y; Ahmed, KA; Anaya, DA; Biebel, B; Choi, J; El-Haddad, G; Frakes, JM; Hoffe, SE; Kim, R; Kim, Y; Kis, B; Malafa, M; Naghavi, AO; Sweeney, J; Venkat, PS | 1 |
| Dehm, K; Helmberger, TK; Hoffmann, RT; Jakobs, TF; La Fougere, C; Murthy, R; Reiser, MF; Stemmler, HJ; Tatsch, K; Trumm, C | 1 |
| Amesur, NB; Devera, MB; Fontes, P; Gamblin, TC; Geller, DA; Heckman, JT; Holloway, SE; Marsh, JW; Nalesnik, M; Steel, JL | 1 |
| Hamm, B; Jahnke, K; Kiewe, P; Korfel, A; Maza, S; Munz, DL; Thiel, E | 1 |
| Aricò, D; Baio, SM; Bartolomei, M; Bodei, L; Botteri, E; Cremonesi, M; De Cicco, C; Grana, CM; Paganelli, G; Sansovini, M | 1 |
| Leahy, MF; Turner, JH | 1 |
| Eidherr, H; Hoffmann, M; Jonak, C; Muellauer, L; Raderer, M; Traub-Weidinger, T; Troch, M | 1 |
| Assisi, D; D'Andrea, M; Dessanti, L; Maini, CL; Petti, MC; Pisani, F; Sciuto, R | 1 |
| Anne, PR; Brown, DB; Doyle, LA; Eschelman, DJ; Frangos, A; Gonsalves, CF; McCann, JW; Petroziello, MF; Sato, T | 1 |
| Gensure, RH; Haffty, BG; Jabbour, SK; Narra, V; Nosher, JL; Patel, B; Schonewolf, CA | 1 |
| Ansell, SM; Habermann, TM; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Fink-Bennett, DM; Thomas, K | 1 |
| Dunn, WL; Leigh, BR; Stabin, MG; White, CA; Wiseman, GA | 1 |
| Alavi, A; Goldenberg, DM; Hartzell, KB; Klumpp, TR; Luger, SM; Maillard, I; Nasta, SD; Porter, DL; Schuster, SJ; Sharkey, RM; Stadtmauer, EA; Tsai, DE | 1 |
| Boerman, OC; Buijs, WC; Oyen, WJ; Postema, EJ | 1 |
| Bartolomei, M; Bodei, L; Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Lamperti, E; Milanesi, I; Paganelli, G; Rocca, P; Salmaggi, A; Silvani, A | 1 |
| Fisher, J; Giap, H; Hillebrand, DJ; Marsh, C; Miller, W; Rivera, L; Schaffer, RL | 1 |
| Altavilla, G; Arrigo, C; Baldari, S; Naro, C; Perniciaro, F; Pitini, V | 1 |
| Darif, M; Emmanouilides, C; Flinn, IW; Gordon, LI; Macklis, R; Molina, A; Schilder, RJ; Vo, K; Wiseman, GA; Witzig, TE | 1 |
| DeMonaco, NA; Jacobs, SA; Joyce, J; McCarty, KS | 1 |
| Fontana, X; Italiano, A; Peyrade, F; Peyrottes, I; Thyss, A | 1 |
| Adamson, PC; Angiolillo, A; Ayello, J; Cairo, MS; Cooney-Qualter, E; Fawwaz, RA; Harrison, L; Kohl, V; Krailo, M; Perkins, SL; vande Ven, C; Wiseman, G | 1 |
| Falk, P; Forman, SJ; Fung, HC; Krishnan, A; Molina, A; Nademanee, A; Palmer, JM; Raubitschek, AA; Rodriguez, R; Spielberger, RT; Yamauchi, D | 1 |
| Abdel-Misih, R; Dignazio, M; Garcia, M; Khatri, J; Neff, R; Petrelli, N; Wilson, P | 1 |
| Lim, LG; Thamboo, TP; Wai, CT; Wang, SC | 1 |
| Bullimore, J; Chandler, C; Coakham, H; Hopkins, K; Kemshead, JT; Sandeman, D | 1 |
| Hopkins, K; Kemshead, JT; Papanastassiou, V | 1 |
| Chan, M; Ho, R; Ho, S; Johnson, PJ; Lau, WY; Leung, TW; Li, AK | 1 |
| Chandler, C; Eatough, J; Hopkins, K; Kemshead, JT; Moss, T | 1 |
| Blackburn, TP; Doughty, D; Plowman, PN | 1 |
| Bartolomei, M; Broggi, G; Caliceti, P; Chinol, M; Cremonesi, M; Ferrari, M; Gatti, M; Grana, C; Maira, G; Paganelli, G; Prisco, G; Sturiale, C | 1 |
| Bartolomei, M; Caliceti, P; Chinol, M; De Cicco, C; Fiorenza, M; Gatti, M; Grana, C; Mazzetta, C; Paganelli, G; Robertson, C | 1 |
| Alcindor, T; Witzig, TE | 1 |
| Arany, I; Hajda, M; Julow, J; Lányi, F; Pásztor, E; Simkovics, M; Tóth, S | 1 |
6 review(s) available for yttrium radioisotopes and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
Topics: Ablation Techniques; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver; Liver Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiosurgery; Treatment Outcome; Yttrium Radioisotopes | 2019 |
Radioembolization for Hepatocellular Carcinoma in Downstaging and Bridging for Liver Transplantation.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Yttrium Radioisotopes | 2020 |
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting.
Topics: Antigens, CD20; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Radioimmunotherapy; Tissue Distribution; Yttrium Radioisotopes | 2022 |
Radioembolization for the treatment of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver; Liver Neoplasms; Mastectomy, Segmental; Neoplasm Recurrence, Local; Radiopharmaceuticals; Yttrium Radioisotopes | 2017 |
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Palliative Care; Radiation Protection; Radioimmunotherapy; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Yttrium Radioisotopes | 2003 |
Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome; Yttrium Radioisotopes | 2002 |
21 trial(s) available for yttrium radioisotopes and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosphate; Adipose Tissue; Administration, Intravaginal; Adolescent; Adsorption; Adult; Adverse Childhood Experiences; Age Distribution; Age Factors; Aged; Aged, 80 and over; Air Pollution, Indoor; Aldehyde Oxidase; Alginates; Alloys; alpha-Globins; Aluminum Hydroxide; Alveolar Bone Loss; Anaerobiosis; Anesthesia, General; Anesthetics; Animals; Anovulation; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bacillus cereus; Bacterial Typing Techniques; Bacteroidetes; Base Composition; Biocompatible Materials; Biofilms; Biological Availability; Biological Transport; Biosensing Techniques; Bipolar Disorder; Blood Glucose; Body Mass Index; Bone Regeneration; Boranes; Brachial Artery; Butyric Acid; Candida albicans; Carbon; Carcinoembryonic Antigen; Cell Differentiation; Cell Line, Tumor; Cell Respiration; Cell Survival; Cells, Cultured; Cerebrovascular Circulation; Charcoal; Child; Child Health; China; Chloride Channels; Chlorides; CHO Cells; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromium; Chronic Disease; Chronic Periodontitis; Circular Dichroism; Cities; Cohort Studies; Comamonadaceae; Comorbidity; Coronary Artery Disease; Corrosion; Cricetinae; Cricetulus; Cross Infection; Cross-Sectional Studies; Crowding; Culture Media; Cytokines; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diarylheptanoids; Diclofenac; Disability Evaluation; Diterpene Alkaloids; DNA; DNA Mutational Analysis; DNA, Bacterial; Drug Liberation; Drug Resistance, Multiple, Bacterial; Electrochemical Techniques; Electrodes; Electrolytes; Endothelium, Vascular; Enterococcus faecalis; Epithelial Cell Adhesion Molecule; Epithelial Cells; Erbium; Erythropoietin; Ethanol; Ethylenediamines; Fast Foods; Fatty Acids; Female; Fermentation; Ferric Compounds; Fibroblasts; Flavobacteriaceae; Fluorides; Fluorodeoxyglucose F18; Food Microbiology; Formaldehyde; Furaldehyde; Gamma Cameras; Gene Expression; Geologic Sediments; Glucose Tolerance Test; Glycated Hemoglobin; Glycolipids; Glycosylation; Gracilaria; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Guanine; Health Surveys; HeLa Cells; Hemoglobins, Abnormal; Hexosamines; High Fructose Corn Syrup; High-Intensity Interval Training; Hip Fractures; Hippocampus; HLA-B27 Antigen; Hospitalization; Housing; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hydroxides; Hypercapnia; Hypertension; Hypocreales; Hypromellose Derivatives; Image Processing, Computer-Assisted; Incidence; Indole Alkaloids; Indonesia; Inflammation Mediators; Infrared Rays; Insulin Resistance; Intercalating Agents; Ion Transport; Ionophores; Japan; Kinetics; Kluyveromyces; Letrozole; Linear Models; Lipopolysaccharides; Liposomes; Liver; Lung Diseases; Magnesium Hydroxide; Magnetic Resonance Spectroscopy; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Microscopy, Electron, Transmission; Middle Aged; Mitochondria; Mitochondria, Muscle; Molecular Docking Simulation; Molecular Structure; Muscle, Skeletal; Mutant Proteins; Mutation; Mutation, Missense; Nanocomposites; Nanoparticles; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nucleic Acid Hybridization; Obesity; Occupational Exposure; Oceans and Seas; Odds Ratio; Organometallic Compounds; Osteogenesis; Ovulation Induction; Oxidation-Reduction; Particle Size; Periodontal Ligament; Permeability; Phaseolus; Phenotype; Philippines; Phosphatidylethanolamines; Phospholipids; Photochemical Processes; Phylogeny; Pichia; Pigmentation; Plant Extracts; Polycystic Ovary Syndrome; Polysaccharides; Postprandial Period; Pregnancy; Pregnancy Rate; Prevalence; Product Surveillance, Postmarketing; Progesterone; Progestins; Protein Engineering; Pseudomonas aeruginosa; Psoriasis; Public Facilities; Rats; Rats, Wistar; Receptors, Thyrotropin; Recombinant Proteins; Reproducibility of Results; Republic of Korea; Retrospective Studies; Rhodobacteraceae; Risk; Risk Assessment; Risk Factors; RNA, Ribosomal, 16S; ROC Curve; Saccharomyces cerevisiae; Salinity; Saliva; Seawater; Seaweed; Sensitivity and Specificity; Sequence Analysis, DNA; Sex Factors; Silver Compounds; Smokers; Social Class; Socioeconomic Factors; Soil Microbiology; Solubility; Soy Foods; Spectrometry, Mass, Electrospray Ionization; Spondylitis, Ankylosing; Staphylococcus aureus; Static Electricity; Steroids; Strontium; Sucrose; Surface Properties; Survival Rate; Sweden; Swine; Synapses; Synchrotrons; Tandem Mass Spectrometry; Tannins; Tea; Temperature; Terpenes; Thalidomide; Thermodynamics; Thiadiazoles; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Time Factors; Tissue Distribution; Titanium; Toilet Facilities; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Ubiquinone; Urinary Tract Infections; Vaginal Creams, Foams, and Jellies; Venezuela; Vitamin K 2; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Microbiology; Water Pollutants, Chemical; Whole Body Imaging; X-Ray Diffraction; Young Adult; Ytterbium; Yttrium; Yttrium Radioisotopes; Zinc Compounds | 2018 |
Consolidation with
Topics: Adult; Aged; Antibodies, Monoclonal; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Poland; Prognosis; Prospective Studies; Radioimmunotherapy; Survival Rate; Yttrium Radioisotopes | 2019 |
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radioimmunotherapy; Salvage Therapy; Survival Rate; Tissue Distribution; Yttrium Radioisotopes | 2013 |
Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Colorectal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Yttrium Radioisotopes | 2014 |
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Radioimmunotherapy; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Burkitt Lymphoma; Case-Control Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radioimmunotherapy; Remission Induction; Retrospective Studies; Survival Rate; Young Adult; Yttrium Radioisotopes | 2015 |
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Radioimmunotherapy; Survival Rate; Yttrium Radioisotopes | 2016 |
Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma.
Topics: Adult; Aged; Antigens, CD20; Antineoplastic Agents; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Rituximab; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2016 |
Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Survival Rate; Yttrium Radioisotopes | 2008 |
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Central Nervous System Neoplasms; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Survival Rate; Tissue Distribution; Yttrium Radioisotopes | 2009 |
Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult; Yttrium Radioisotopes | 2009 |
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Side-branch embolization before 90Y radioembolization: rate of recanalization and new collateral development.
Topics: Adult; Aged; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Radiography; Radiopharmaceuticals; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Prospective Studies; Radioimmunotherapy; Rituximab; Salvage Therapy; Tissue Distribution; Tomography, Emission-Computed; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Delivery Systems; Glioblastoma; Humans; Infusions, Intralesional; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Radioimmunotherapy; Yttrium Radioisotopes | 2005 |
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Immunoconjugates; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2007 |
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Bone Marrow; Child; Child, Preschool; Female; Humans; Immunoconjugates; Indium Radioisotopes; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Radiation Dosage; Radioimmunotherapy; Radiotherapy Dosage; Rituximab; Tissue Distribution; Yttrium Radioisotopes | 2007 |
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Stem Cell Transplantation; Treatment Outcome; Yttrium Radioisotopes | 2008 |
The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates.
Topics: Antibodies, Monoclonal; Brain Neoplasms; Dose-Response Relationship, Radiation; Glioma; Humans; Immunoconjugates; Injections, Intralesional; Iodine Radioisotopes; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Radioimmunotherapy; Radiotherapy Dosage; Relative Biological Effectiveness; Survival Rate; Yttrium Radioisotopes | 1996 |
Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
Topics: Adult; Aged; Antibodies, Monoclonal; Avidin; Biotin; Brain Neoplasms; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Radiotherapy Dosage; Tenascin; Tissue Distribution; Yttrium Radioisotopes | 2001 |
Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Avidin; Biotin; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2002 |
36 other study(ies) available for yttrium radioisotopes and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Radioimmunotherapy; Tissue Distribution; Transplantation Conditioning; Tumor Microenvironment; Yttrium Radioisotopes | 2021 |
The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Consensus; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Pharmaceutical Preparations; Quality of Life; Treatment Outcome; Turkey; Yttrium Radioisotopes | 2021 |
Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Cholecystectomy; Fatal Outcome; Fluorouracil; Hepatectomy; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Reoperation; Time Factors; Yttrium Radioisotopes | 2021 |
A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatectomy; Humans; Hypertrophy; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; New York City; Retrospective Studies; Yttrium Radioisotopes | 2021 |
[Current surgical treatment for hepatocellular carcinoma : critical appraisal of current guidelines].
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
Topics: alpha-Fetoproteins; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Effectiveness of Hepatic Artery Infusion (HAI) Versus Selective Internal Radiation Therapy (Y90) for Pretreated Isolated Unresectable Colorectal Liver Metastases (IU-CRCLM).
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Colorectal Neoplasms; Combined Modality Therapy; Embolization, Therapeutic; Female; Floxuridine; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Yttrium Radioisotopes | 2018 |
Inconclusive benefit of adjuvant
Topics: Adult; Durapatite; Female; Follow-Up Studies; Humans; Injections, Intra-Articular; Knee Joint; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Retrospective Studies; Synovectomy; Synovial Membrane; Synovitis, Pigmented Villonodular; Treatment Outcome; Yttrium Radioisotopes | 2018 |
Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.
Topics: Adult; Aged; Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Regeneration; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2018 |
Transarterial Radiation Lobectomy, Portal Vein Embolization, and Staged Hepatectomy for Multiple Bilobar Metachronous Colorectal Liver Metastasis.
Topics: Angiography; Colorectal Neoplasms; Embolization, Therapeutic; Hepatectomy; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Portal Vein; Yttrium Radioisotopes | 2018 |
Repeated Treatment with
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Radiotherapy, Adjuvant; Retreatment; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2019 |
The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee.
Topics: Adult; Brachytherapy; Female; Humans; Knee Joint; Male; Middle Aged; Neoplasm Recurrence, Local; Radiopharmaceuticals; Synovectomy; Synovitis, Pigmented Villonodular; Yttrium Radioisotopes | 2019 |
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Topics: Aged; Angiography, Digital Subtraction; Carcinoma, Hepatocellular; Disease Progression; Embolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2014 |
Liver resection for metastatic disease after y90 radioembolization: a case series with long-term follow-up.
Topics: Aged; Combined Modality Therapy; Embolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Size; Spleen; Yttrium Radioisotopes | 2015 |
Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Yttrium Radioisotopes | 2015 |
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Cholangiocarcinoma; Embolization, Therapeutic; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Yttrium Radioisotopes | 2016 |
Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Embolization, Therapeutic; Female; Florida; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Proportional Hazards Models; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
Topics: Antineoplastic Agents; Brachytherapy; Colorectal Neoplasms; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome; Yttrium Radioisotopes | 2008 |
90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2011 |
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Rituximab; Vidarabine; Yttrium Radioisotopes | 2011 |
Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.
Topics: Adult; Aged; Colorectal Neoplasms; Disease-Free Survival; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Resins, Synthetic; Retrospective Studies; Risk Assessment; Risk Factors; Salvage Therapy; Tomography, X-Ray Computed; Treatment Failure; Yttrium Radioisotopes | 2014 |
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Treatment Outcome; Yttrium Radioisotopes | 2002 |
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte; B-Lymphocytes; Cell Adhesion Molecules; Disease Progression; Humans; Lectins; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Radiopharmaceuticals; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Underestimation of absorbed dose to kidney.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Humans; Kidney; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasm Recurrence, Local; Radiation Dosage; Radioimmunotherapy; Radiotherapy Dosage; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.
Topics: Adult; Carcinoma, Hepatocellular; Hepatitis C; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Liver Transplantation; Male; Microspheres; Neoplasm Recurrence, Local; Neoplasm Staging; Treatment Outcome; Yttrium Radioisotopes | 2006 |
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Lymphoma; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Salvage Therapy; Survival Rate; Temozolomide; Yttrium Radioisotopes | 2007 |
Focal radiation fibrosis after radioimmunotherapy for follicular non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Diagnosis, Differential; Dose-Response Relationship, Radiation; Humans; Laryngeal Neoplasms; Lung Neoplasms; Lymphoma, Follicular; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiation Pneumonitis; Radioimmunotherapy; Recurrence; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2007 |
Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment.
Topics: Aged; Antibodies, Monoclonal; Humans; Lymphoma, Follicular; Male; Neoplasm Recurrence, Local; Radioimmunotherapy; Retreatment; Yttrium Radioisotopes | 2007 |
The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Yttrium Radioisotopes | 2008 |
Late gastric ulceration and cytomegalovirus infection following selective internal radiation therapy (SIRT) of the liver.
Topics: Aged; Ascites; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cytomegalovirus Infections; Diabetes Mellitus; Hepatic Artery; Humans; Hypertension; Hypertension, Portal; Infusions, Intra-Arterial; Liver Cirrhosis; Liver Neoplasms; Male; Microspheres; Neoplasm Recurrence, Local; Stomach Ulcer; Yttrium Radioisotopes | 2008 |
A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates.
Topics: Adolescent; Adult; Aged; Antigens, Surface; Bone Marrow; Brain Edema; Brain Neoplasms; Cell Adhesion Molecules, Neuronal; Child; Dexamethasone; Feasibility Studies; Female; Glioma; Humans; Immunoconjugates; Injections, Intralesional; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Radioimmunotherapy; Radiotherapy Dosage; Yttrium Radioisotopes | 1995 |
Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cause of Death; Dose Fractionation, Radiation; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Survival Analysis; Yttrium Radioisotopes | 1998 |
Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose.
Topics: Antibodies, Monoclonal; Biopsy; Brain; Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Immunoconjugates; Injections, Intralesional; Models, Biological; Neoplasm Recurrence, Local; Radioimmunotherapy; Yttrium Radioisotopes | 1998 |
Stereotactic intracavitary therapy of recurrent cystic craniopharyngioma by instillation of 90yttrium.
Topics: Adult; Brachytherapy; Child; Craniopharyngioma; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pituitary Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome; Vision Disorders; Yttrium Radioisotopes | 1999 |
The radiotherapy of cystic craniopharyngioma with intracystic installation of 90Y silicate colloid.
Topics: Adolescent; Adult; Brachytherapy; Child; Combined Modality Therapy; Craniopharyngioma; Cysts; Female; Humans; Male; Neoplasm Recurrence, Local; Pituitary Neoplasms; Silicates; Tomography, X-Ray Computed; Yttrium; Yttrium Radioisotopes | 1985 |